As we conclude 2025, we would like to thank all our partners, clients, and colleagues for their trust and collaboration throughout the year.
During whole year 2025 we continued in turning complex development challenges into tangible progress for our partners and, ultimately, for patients.
Together in 2025, we for example:
- Connected with industry leaders at CPHI 2025 in Frankfurt, strengthening existing relationships and opening the door to new collaborations.
- Earned a Bronze EcoVadis Medal and improved our score in an independent ESG rating, confirming our long-term commitment to responsible and sustainable operations.
- Joined the United Nations Global Compact, further aligning our business with internationally recognised principles on human rights, labour, the environment, and anti-corruption.
- Published an article on preclinical bioanalysis accelerating clinical entry, highlighting how robust analytical support can de-risk and speed up early development.
- Shared a client testimonial with Herantis Pharma Plc on HER-096, a novel approach aiming to slow or even halt the progression of Parkinson’s disease – with Quinta-Analytica as a trusted analytical partner.
- Published a case study on taking midazolam into a buccal film together with our partner Swipp, helping bring the world’s first-ever midazolam buccal film into clinical trials.
This is just a tiny sample of our activities – and none of it would have been possible without the dedication of our teams in Prague, Brno, and Ostrava, whose scientific excellence and flexibility continue to make Quinta-Analytica a reliable development partner.
Thank you for being part of our 2025 journey.
We look forward to innovating and growing together in the year ahead and to supporting your next projects with the same commitment to quality, agility, and partnership.
Wishing you a successful and inspiring 2026!
Quinta-Analytica Team
